Spyryx Biosciences
Manufacturing · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
801 Capitola Dr Ste 10, Durham, North Ca...Phone Number
(919) 899-9399Website
www.spyryxbio.comRevenue
$6.3 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Spyryx Biosciences
Spyryx Biosciences is a clinical-stage biopharmaceutical company developing innovative therapeutics to address severe pulmonary diseases. Spyryx's lead clinical candidate, SPX-101, is completing a multinational Phase 2 study as a novel treatment for cystic fibrosis. The product has demonstrated a robust ability to restore mucociliary clearance in animal models of the disease. SPX-101 has also been shown to be safe and well tolerated in a completed Phase 1b in adult patients with cystic fibrosis and has the potential to improve lung function in all people living with cystic fibrosis independent of their genotype. Spyryx is funded by a first-tier syndicate of life science investors, including Canaan, 5AM Ventures and Hatteras Venture Partners - as well as the Cystic Fibrosis Foundation.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Spyryx Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Spyryx Biosciences has new funding data
Product Launch: Get notified when Spyryx Biosciences launches new products
Check if Spyryx Biosciences has recently received funding, and reach out quickly before it becomes old news!
Check out if Spyryx Biosciences is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Spyryx Biosciences
Click to see if Spyryx Biosciences had a recent Job posting/layoffs
Earning: See what the market has to say on Spyryx Biosciences recently announced quarterly report
Spyryx Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Spyryx Biosciences
Compare insights from companies similar to Spyryx Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Spyryx Biosciences
$6.3M
11-50
Private
$23M
2013
N/A
Company Profile Activity
Activity Insights
Spyryx Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Spyryx Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Spyryx Biosciences.
Spyryx Biosciences financials insights
Gather financial insights about Spyryx Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$18M
2017
Debt
$5M
Spyryx Biosciences Tech Stack
A closer look at the technologies used by Spyryx Biosciences
See more technologies
Spyryx Biosciences News & Media
Data from Spyryx Biosciences' HOPE-1 Phase 2 Clinical Trial to be Presented in a Late-Breaking Oral Presentation at the 41st European Cystic Fibrosis Conference
DURHAM, N.C., May 8, 2018 /PRNewswire/ -- Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for severe pulmonary diseases, will present data from the first cohort of its ongoing Phase 2 clinical trial, HOPE-1, in a late-breaking oral...Positive Pre-Clinical Data Supporting SPX-101 to be Presented at the North American Cystic Fibrosis Conference
DURHAM, N.C., Nov. 1, 2017 /PRNewswire/ -- Spyryx Biosciences, Inc., will share positive data this week highlighting additional insights into the mechanism of action and pharmacological importance of SPX-101, the Company's pipeline therapeutic treatment for cystic fibrosis (CF), at NACFC...Spyryx Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of SPX-101 for the Treatment of Cystic Fibrosis
DURHAM, N.C., Oct. 18, 2017 /PRNewswire/ -- Spyryx Biosciences, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics to address severe respiratory diseases, today announced the first patient was dosed in the HOPE-1 study, a multinational Phase 2 clinical...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Spyryx Biosciences
Sign Up For FreeTo access detailed company insights
Spyryx Biosciences is a clinical-stage biopharmaceutical company developing innovative therapeutics to address severe pulmonary diseases. Spyryx's lead clinical candidate, SPX-101, is completing a multinational Phase 2 study as a novel treatment for cystic fibrosis. The product has demonstrated a robust ability to restore mucociliary clearance in a... Read More
